SciRhom Secures €63 Million in Series A Funding for Autoimmune Therapies

1. Funding Amount: SciRhom has raised €63 million in a Series A funding round to accelerate its therapeutic strategy for autoimmune disorders.
2. Investor Syndicate: The funding was led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors.
3. Therapeutic Focus: SciRhom is developing first-in-class therapeutic iRhom2 antibodies to address autoimmune diseases, with a focus on selectively targeting TACE/ADAM17, a key signaling pathway.
4. Lead Program: The company's lead development program, SR-878, is a highly specific monoclonal antibody for iRhom2, with the first clinical study expected to start dosing in the second half of 2024.
5. Clinical Study: The study aims to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in patients with autoimmune disorders.
6. Board Additions: Dr. Olivier Litzka from Andera Partners, Dr. Peter Neubeck from Kurma Partners, Dr. Georgina Askeland from Hadean Ventures, Dr. Fei Tian from MIG Capital, and Dr. Varun Gupta from Wellington Partners will join SciRhom's Board of Directors.